Onyx Newsroom

Featured

How Epicrispr are leading the first epigenetic editing trial for muscular dystrophy

Four years of progression-free survival: Nuvation Bio wins FDA approval for lung cancer

Affinia closes $40m Series C: CEO Rick Modi explains how low-dose gene therapy capsids could cure cardiomyopathy

“Over the past year, we have made tremendous progress…” Rick Modi says, as Affinia Therapeutics pushes its BAG3-DCM program toward first-in-human testing, aiming to prove that next-generation capsids can restore heart function at dramatically lower doses.

Press releases

Jefferies Global Healthcare Conference in London

, and Press Releases

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

, and Press Releases

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

, and Press Releases

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

, and Press Releases

Second Opinion

See all

From sickness to prevention: How welfare cuts risk undermining the UK's 10-Year Health Plan

“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.

Moloch and Medicine: why good intentions built a broken system, and why CGT might fix it all (sort of)

Anis Fahandej-Sadi breaks down the big problems with current incentive structures

Finding balance in the noise

"Almost a third of over-65s will fall each year," but could nGVS represent a discreet tool against imbalance?

Sick enough: the silent struggles of sub-clinical illness in modern medicine

To live in the grey zone of sub-clinical pathology is to be unwell enough to hurt, but not enough to be heard.

In the Company of Shadows: Love, Labour, and the Long Way Through

First-generation medical students carry two textbooks - one devoted to anatomy, the other towards cultivating resilience.

Gut Feelings: Harnessing the Gut Microbiome to Manage Anxiety in Primary Care

Trillions of microbes inside us are not mere bystanders, but quiet architects of our moods.

The rise of Chinese pharmaceuticals and biotech

"These projects are more than acts of goodwill," China's Health Silk Road is as much about soft power as it is about medicine.

More than just a headache

“Pain is treated like a badge of honor" in medicine, but the cost is a workforce breaking under invisible pressure.

Artificial intelligence in skin cancer diagnosis: Improving diagnostics and reducing health disparity

"AI has already been shown to be just as, if not more, accurate than dermatologists," Dr. Alexander Green explains, as DERM proves 99.8% effective at ruling out cancer.

Martial law targets resident physicians: implications for the healthcare crisis in South Korea

Industrial relations between doctors and the state have never been worse

Drug Discovery

A Legend in the making: how Ying Huang is scaling CAR-T to global markets

“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.

From Grammys to Gene Therapy: Gaurav Shah’s Rocket-Fueled Revolution in Rare Diseases

A Grammy-winning CEO is taking gene therapy to new heights.

Let there Belite: an oral pill for vision loss

If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope.

A deep dive into one of the fastest growing biotechs of all time

Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.

Inside the world’s most innovative square mile: MassBio leads the life sciences

Kendalle Burlin O’Connell tells us about the privilege of heading up MassBio - the organization that represents the extraordinary life sciences sector in Massachusetts.